Technical Coverage on Biotech Stocks -- Research on Athersys, Lexicon Pharma, Biogen Idec, and Theravance
PR Newswire - Mon May 12, 11:30AM CDT
On Friday, May 09, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, and the index has advanced 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Athersys Inc. (NASDAQ: ATHX), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Biogen Idec Inc. (NASDAQ: BIIB) and Theravance Inc. (NASDAQ: THRX). Free technical research on ATHX, LXRX, BIIB and THRX can be downloaded upon signing up at:
Traumatic Brain Injury - Pipeline Review, H1 2014: Includes 42 Company and 72 Drug Profiles
M2 - Mon May 12, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vqxgvm/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - ALSP, Inc. - Acorda Therapeutics, Inc. - Adamas Pharmaceuticals, Inc. - Allinky Biopharma - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Bionature E.A. Ltd. - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - D-Pharm Ltd. - Encore Therapeutics Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - Intellect Neurosciences, Inc. - Io Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - M's Science Corporation - MAPREG - MandalMed, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - NeuroHealing Pharmaceuticals Inc. - NeuroNascent, Inc. - NeuroVive Pharmaceutical AB - Omeros Corporation - Oxygen Biotherapeutics, Inc. Drug Profiles: - epoetin alfa - progesterone - progesterone - NeuroSTAT - Oxycyte - VAS-203 - NH-001 - NNZ-2566 - atorvastatin calcium - NeuroSTAT - glyburide - Allopregnanolone - VOLT-02 - SB-623 - RGS-2064 - DP-b99 - amantadine hydrochloride - Drug for Traumatic Brain Injury - MAP-4343 - Posiphen - MultiStem - Lpathomab - RGN-352 - cutamesine - INN-01 - NSI-189 - COG-1410 - AMR-001 - NSI-566 - LB-201 For more information visit http://www.researchandmarkets.com/research/vq...atic_brain
Athersys Reports First Quarter 2014 Results
GlobeNewswire - Thu May 08, 3:48PM CDT
Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended March 31, 2014.
Schizophrenia - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Thu May 08, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49rlth/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Schizophrenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AGY Therapeutics, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Acino Pharma AG - Adamed Sp. z o.o. - Addex Therapeutics - Aestus Therapeutics, Inc. - Alkermes Plc - Angita B.V. - Ascendis Pharma A/S - Astellas Pharma Inc. - Athersys, Inc. - BIOPROJET SCR - BRAINco Biopharma, S.L. - BioCrea GmbH - Bionomics Limited - Biotie Therapies Corp. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Dainippon Sumitomo Pharma Co., Ltd. - Delpor, Inc. - Domain Therapeutics SA - Dongwha Pharm Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/49...izophrenia
The Biggest Biotech Catastrophes of the Week
Cory Renauer, The Motley Fool - Motley Fool - Wed May 07, 1:30PM CDT
Last week was rough for clinical stage biotechnology companies. Three watched their market caps dissolve after reporting lead candidate failures. Endocyte had an abrupt reversal of fortune, while OncoGenex Pharmaceuticals found out its...
Inflammatory Bowel Disease - Pipeline Review, H1 2014: 73 Companies and 135 Drugs Profiled
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/rmqbbx/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - ASKA Pharmaceutical Co., Ltd. - ActogeniX NV - Addex Therapeutics - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - AlbireoPharma - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Antibe Therapeutics, Inc. - Aquinox Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Athersys, Inc. - Atlantic Healthcare Limited - Axxam SpA - Basilea Pharmaceutica AG - BioLineRx, Ltd. - Biotec Pharmacon ASA - Boehringer Ingelheim GmbH - Catabasis Pharmaceuticals, Inc. - Celsus Therapeutics Plc - ChironWells GmbH - Complix NV - Compugen Ltd. - Creabilis SA - Delenex Therapeutics AG - Eisai Co., Ltd. - Emergent BioSolutions Inc. - Ensemble Discovery Corporation For more information visit http://www.researchandmarkets.com/research/rm...flammatory
Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Global Forecasts to 2020
M2 - Tue May 06, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wwnrd5/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020" report to their offering. The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. The allogeneic stem cell therapy is expected to command the largest share of the market in 2015, and is also expected to grow at a higher CAGR than autologous therapies from 2015 to 2020. Based on the therapeutic applications, the global market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others. A number of factors such as increasing funding from government and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are driving the growth of the global market. Furthermore, increasing funding for new stem cell lines, development of advanced genomic methods for stem cell analysis, and rising approvals of clinical trials for stem cells therapy are other factors that are propelling the growth of the market. Key Topics Covered: 1 INTRODUCTION 2 EXECUTIVE SUMMARY 3 MARKET DYNAMICS 4 PIPELINE ANALYSIS 5 INVESTOR NETWORK 6 GLOBAL STEM CELL THERAPY MARKET, BY MODE OF THERAPY 7 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATIONS 8 REGULATORY LANDSCAPE 9 GLOBAL STEM CELL THERAPY MARKET, BY GEOGRAPHY 10 COMPETITIVE LANDSCAPE 11 COMPANY PROFILES Companies Mentioned: - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Athersys Inc. - Celgene Corporation - Cellular Dynamics International - Cytori Therapeutics, Inc. - Fibrocell Science, Inc. - Gamida Cell Ltd. - Mesoblast Ltd. - Pluristem Therapeutics Inc. - StemCells Inc. For more information visit http://www.researchandmarkets.com/research/ww...ll_therapy
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
Athersys (ATHX) in Focus: Stock Slumps 51.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 7:40AM CDT
Athersys has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Nasdaq stocks posting largest volume increases
AP - Mon Apr 28, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Bank of America, AstraZeneca are big market movers
AP - Mon Apr 28, 4:52PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
Why Athersys (ATHX) Stock Plummeted to a One-Year Low Today
at The Street - Mon Apr 28, 12:50PM CDT
Athersys (ATHX) plummeted to a one-year low after the company announced the failure of its experimental ulcerative colitis treatment in a mid-stage trial.
Senators Support Regenerative Medicine Promotion Act of 2014
ACCESSWIRE - Mon Apr 28, 11:46AM CDT
Whitefish, MT / April 28, 2014 / Last month, the regenerative medicine industry received important support that could facilitate a road map to accelerate the discovery of new therapies for some of the world's most hard-to-treat and cost-intensive diseases and conditions. Senators Mark Kirk (R-IL) and Barbara Boxer (D-CA) introduced the Regenerative Medicine Promotion Act of 2014 in the U.S. Senate seeking to establish a national strategy to support regenerative medicines and a Regenerative Medicine Coordinating Council.
Stock to Watch: Athersys Down 57.3% (ATHX)
Comtex SmarTrend(R) - Mon Apr 28, 10:10AM CDT
Athersys (NASDAQ:ATHX) is one of today's worst performing low-priced stocks, down 57.3% to $1.17 on 7.7x average daily volume. Athersys has traded 8.0 million shares thus far today, vs. average volume of 1.0 million shares per day. The stock has underperformed the Dow (-57.3% to the Dow's 0.7%) and underperformed the S&P 500 (-57.3% to the S&P's 0.5%) during today's trading.
Athersys Announces Results From Phase 2 Study of MultiStem(R) Cell Therapy for Ulcerative Colitis
GlobeNewswire - Mon Apr 28, 6:13AM CDT
Athersys, Inc. (Nasdaq:ATHX) today announced interim results from the Phase 2 clinical study of the administration of Athersys' MultiStem cell therapy to treatment refractory ulcerative colitis (UC) patients being conducted by Pfizer, Inc. The study results demonstrate favorable safety and tolerability for MultiStem through 8 weeks following treatment. However, the cell therapy failed to show meaningful benefit, following a single administration, in patients suffering from chronic, moderate-to-severe UC who have failed other therapies. These results reflect patient data 8 weeks following cell therapy or placebo administration and include the primary efficacy endpoints for the study. Additional 16-week results, including data about the impact from a second round of dosing for a subset of patients, longer term secondary clinical endpoints, and biomarker evaluation will be available after additional analysis has been completed.
Zacks Rank #5 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
Athersys to Host First Quarter 2014 Financial Results Call
GlobeNewswire - Wed Apr 16, 10:30AM CDT
Athersys, Inc. (Nasdaq:ATHX) will release its first quarter 2014 financial results at approximately 4:00 PM (Eastern Time) on Thursday, May 8, 2014, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday